JP2013533287A - 嗅覚機能不全の処置のためのラサギリンの使用 - Google Patents

嗅覚機能不全の処置のためのラサギリンの使用 Download PDF

Info

Publication number
JP2013533287A
JP2013533287A JP2013521949A JP2013521949A JP2013533287A JP 2013533287 A JP2013533287 A JP 2013533287A JP 2013521949 A JP2013521949 A JP 2013521949A JP 2013521949 A JP2013521949 A JP 2013521949A JP 2013533287 A JP2013533287 A JP 2013533287A
Authority
JP
Japan
Prior art keywords
olfactory
subject
pharmaceutically acceptable
acceptable salt
propargyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013521949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533287A5 (https=
Inventor
ペティ、ゲラルディン
ブルンディン、パトリック
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2013533287A publication Critical patent/JP2013533287A/ja
Publication of JP2013533287A5 publication Critical patent/JP2013533287A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2013521949A 2010-07-27 2011-07-27 嗅覚機能不全の処置のためのラサギリンの使用 Ceased JP2013533287A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40046410P 2010-07-27 2010-07-27
US61/400,464 2010-07-27
US201161437212P 2011-01-28 2011-01-28
US61/437,212 2011-01-28
PCT/US2011/045574 WO2012015950A1 (en) 2010-07-27 2011-07-27 Use of rasagiline for the treatment of olfactory dysfunction

Publications (2)

Publication Number Publication Date
JP2013533287A true JP2013533287A (ja) 2013-08-22
JP2013533287A5 JP2013533287A5 (https=) 2014-10-16

Family

ID=45527351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013521949A Ceased JP2013533287A (ja) 2010-07-27 2011-07-27 嗅覚機能不全の処置のためのラサギリンの使用

Country Status (7)

Country Link
US (1) US8569379B2 (https=)
EP (1) EP2603212A4 (https=)
JP (1) JP2013533287A (https=)
AU (1) AU2011282720B2 (https=)
CA (1) CA2806740A1 (https=)
RU (1) RU2587330C2 (https=)
WO (1) WO2012015950A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
RU2713786C1 (ru) * 2019-05-24 2020-02-07 Сергей Геннадиевич Вахрушев Способ лечения пациентов с обонятельной дисфункцией при атрофическом рините

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151625A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for parkinson's disease modification

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ES2241064T3 (es) 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
US7326690B2 (en) 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
ES2432117T3 (es) 2002-11-15 2013-11-29 Teva Pharmaceutical Industries Limited Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
US20090036448A1 (en) * 2004-03-30 2009-02-05 Taisho Pharmecutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2006014973A2 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
WO2006091657A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2630037C (en) 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
CN101600346B (zh) 2006-12-14 2013-08-21 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20110111014A1 (en) 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
CA2698695A1 (en) 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US8334409B2 (en) 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2010304755A1 (en) 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
SG189454A1 (en) 2010-10-26 2013-05-31 Teva Pharma Deuterium enriched rasagiline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151625A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for parkinson's disease modification

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015024065; Ａｌｖａｒｅｚ，　Ｍ．　Ｖ．　ｅｔ　ａｌ．，　Ｍｏｖｅｍｅｎｔ　Ｄｉｓｏｒｄｅｒｓ，　２０１０，　Ｖｏｌ．２５，　Ｓｕｐｐ．　２，　ｐ．　Ｓ２５５，　Ａｂｓｔｒａｃｔ　Ｎｕｍｂｅｒ：２１１ *
JPN6015024066; Ｓｉｍｕｎｉ，　Ｔ．　ｅｔ　ａｌ．，　Ｅｕｒｏｐｅａｎ　Ｎｅｕｒｏｌｏｇｙ，　２００９，　Ｖｏｌ．６１，　Ｎｏ．４，　ｐ．２０６-２１５ *

Also Published As

Publication number Publication date
US20120029087A1 (en) 2012-02-02
AU2011282720A1 (en) 2013-03-14
AU2011282720B2 (en) 2016-12-22
EP2603212A1 (en) 2013-06-19
RU2587330C2 (ru) 2016-06-20
CA2806740A1 (en) 2012-02-02
US8569379B2 (en) 2013-10-29
EP2603212A4 (en) 2014-01-08
WO2012015950A1 (en) 2012-02-02
RU2013108258A (ru) 2014-09-10

Similar Documents

Publication Publication Date Title
JP2013533287A (ja) 嗅覚機能不全の処置のためのラサギリンの使用
Hare et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures
CN100450475C (zh) 用于治疗注意力缺陷多动障碍及多发性硬化症疲劳的含有莫达非尼的组合物
JP5701485B2 (ja) 多系統萎縮症の治療のためのラサギリンの使用
CN101442997B (zh) 雷沙吉兰用于治疗多动腿综合征
Nicolodi et al. Fibromyalgia and migraine, two faces of the same mechanism: serotonin as the common clue for pathogenesis and therapy
EP2701693B1 (en) Tapentadol for preventing and treating depression and anxiety
US20230310368A1 (en) Mdma enantiomers
CN110461319A (zh) 治疗癫痫发作紊乱和prader-willi综合征的方法
RU2464023C2 (ru) Лекарственное средство для лечения фибромиалгии
US20210205412A1 (en) Methods of inhibiting cerebral inflammation
CN117396200A (zh) 辅助性d-环丝氨酸对重度抑郁症的经颅磁刺激（tms）治疗的增效作用
US20230226020A1 (en) Mdma enantiomers
US20230226019A1 (en) Mdma enantiomers
JP7744419B2 (ja) レット症候群を治療するためのプリドピジンまたはその類似体の使用
US20120309840A1 (en) Treatment of Pain Associated with Trigeminal Neuralgia
JP2022521579A (ja) ピット・ホプキンス症候群の治療
Faghihi et al. Effect of topical 1% tetracaine hydrochloride on intraocular pressure in ophthalmologically normal horses; a pilot study
Zare et al. Wake-Promoting agents; insights into clinical use and molecular perspectives
CN115337307A (zh) 布托啡诺或其盐在制备抗抑郁药物中的新用途
WO2024196772A2 (en) Mdma enantiomers
CA2575204A1 (en) Methods of treating ophthalmic conditions
WO2024253775A1 (en) Mdma enantiomers
US20190274974A1 (en) Treatment of Pain Associated with Trigeminal Neuralgia
Woodlee Mechanisms underlying the dysregulation of postural stability in dopamine-depleted rats

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160531

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20180227